Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 2/20 | 0.64 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.63 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.63 |
| ▸ | GLP1R | P43220 | 9/20 | 0.63 |
| ▸ | GCGR | P47871 | 1/20 | 0.63 |
| ▸ | GIPR | P48546 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 1/20 | 0.61 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498854 | 0.99 | GLP1R (0.64) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL29770921 | 0.96 | VIPR2 (0.65) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL30860116 | 0.96 | GLP1R (0.60) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL30860128 | 0.96 | GLP1R (0.60) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL31743242 | 0.95 | GLP1R (0.61) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL31243561 | 0.94 | KEAP1 (0.67) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL31065739 | 0.93 | GLP1R (0.61) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL29894848 | 0.93 | GLP1R (0.60) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL31009219 | 0.93 | GLP1R (0.61) | PTH1RVIPR2VIPR1GLP1RGCGR | |
| SCHEMBL30860112 | 0.93 | GLP1R (0.61) | VIPR2VIPR1GLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4590326-A1 | COMBINATION THERAPY | Zealand Pharma A/S (DK) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024061919-A1 | COMBINATION THERAPY | ZEALAND PHARMA A/S (DK) | 2024-03-28 | — | — | WO | disclosed |
| US-20220275029-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS, INC. | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | PTH1R 603/4885VIPR2 790/4885VIPR1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.